Perindopril Erbumine

The present work describes a new simple, sensitive and precise reverse phase high performance liquid chromatographic method (RP-HPLC) for the simultaneous estimation of Losartan potassium (LP) and Perindopril erbumine (PE) in bulk and in pharmaceutical dosage forms. Chromatographic separation was performed on KNAUER High Performance Liquid Chromatographic System with C18 column of Make: Thermo Hypersil – ODS of dimensions 250 x 4.6mmwith a mobile phase comprising of 0.01M potassium phosphate buffer (pH 3.5): Acetonitrile: Methanol in the ratio of 5:55:40v/v. the pH of buffer was adjusted with ortho phosphoric acid. The flow rate was 1.0 ml/min with detection with detection at 210nm.As per International Conference on Harmonization (ICH) guidelines the method was validated for linearity, precision, limit of quantitation, limit if detection and robustness. Linearity of LP was found to be in the range of 350µg/ml-650µg/ml and 28µg/ml-52µg/ml for PE. The correlation coefficient for LP and PE was found to be 0.997 and 0.998 respectively. The mean recoveries obtained for LP and PE was found to be 100.222% and 99.844% respectively. The developed analytical method was found to be accurate, linear, specific, and precise which is evident from the statistical data.

The manuscript describes validated Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method for the simultaneous estimation of Perindopril Erbumine and Indapamide in combined dosage form. The RP-HPLC separation was achieved on Intersil ODS C18 column (250 mm x 4.6 mm i.d., 5 µm particle size) at 40oC using mobile phase Acetonitrile : Acid Phthalate Buffer (pH 3.0 ± 0.05) (50 :50, v/v) at flow rate 1.0 mL/min. Quantification was achieved with photodiode array (PDA) detection at 240 nm over the concentration range of 10 - 50 µg/mL for Perindopril Erbumine and 3 - 15 µg/mL for Indapamide with mean recovery of 100.09 ± 0.52 % and 100.13 ± 0.09 % for Perindopril Erbumine and Indapamide, respectively. These methods were found to be simple, sensitive, accurate, precise and economical and applicable for the simultaneous determination of Perindopril Erbumine and Indapamide in combined dosage form.

Floating dosage form for gastric retention has potential to use as controlled-release drug delivery systems which providing opportunity for both local and systemic drug action. The present work was aimed to formulate controlled release floating tablet (CRFT) of Perindopril Erbumine using gas generated low density approach. To develop CRFT, the Perindopril Erbumine was selected as a drug because it complies with the suitability criteria for the floating drug delivery system and the controlled release medication was required due to its potent action and poor bioavailability. The present investigation was suggested that the bioavailability of Perindopril Erbumine was improved due to increased gastric retention time and controlling the drug release rate using the natural polymer SFG, HPMCK15M and Acrypol 934. The CRFT of Perindopril Erbumine was developed by using wet granulation method and PVP K 30 was used as a granulating agent. The study was given the assurance that SFG had an excellent controlled drug releasing property then HPMCK15M by forming matrix in the formulation. The Acrypol 934 was added to control the drug release rate in to formulation and found good compressibility and controllable drug releasing properties in to the final formulation. All the formulation was evaluated for Weight variation, Thickness, Hardness, Diameter, Friability, Assay, FLT, TFT, Swelling Index and Dissolution study. Key Word: CRFT, SFG, Acrypol 934, FLT, TFT, SWI, Perindopril Erbumine, DSC